enfortumab vedotin   Click here for help

GtoPdb Ligand ID: 10738

Synonyms: ASG-22CE | enfortumab vedotin-ejfv | Padcev®
Approved drug
enfortumab vedotin is an approved drug (FDA (2019))
Compound class: Antibody
Comment: Enfortumab vedotin is an anti-Nectin 4 monoclonal antibody-drug conjugate [3]. The toxic payload is monomethyl auristatin E (MMAE; PubChem CID 11542188). It exhibits potent efficacy in multiple preclinical cancer models [1].
No information available.
Summary of Clinical Use Click here for help
Enfortumab vedotin was advanced to clinical trials in cancer patients, in particular for bladder/urothelial cancers [2]. It was FDA approved in 2019 (under the FDA's accelerated approval process), for patients with locally advanced/metastatic urothelial cancer, for which immune checkpoint inhibitor therapies have been unsuccessful. It was the first anti-nectin 4 therapeutic to reach the clinic.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03219333 A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer Phase 2 Interventional Astellas Pharma Inc
NCT03474107 A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) Phase 3 Interventional Astellas Pharma Inc